G Rocheleau1, C J Brumme2, J Shoveller3, V D Lima3, P R Harrigan4. 1. Experimental Medicine, Faculty of Medicine, University of British Columbia, Vancouver, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada. 2. British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada. 3. British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada; School of Population and Public Health, University of British Columbia, Vancouver, Canada. 4. British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada; Division of AIDS, Faculty of Medicine, University of British Columbia, Vancouver, Canada. Electronic address: prharrigan@cfenet.ubc.ca.
Abstract
OBJECTIVES: We aim to identify long-term trends in HIV drug resistance before and after combined antiretroviral therapy (cART) initiation. METHODS: IAS-USA (2015) mutations were identified in 23 271 HIV protease-reverse transcriptase sequences from 6543 treatment naïve adults in British Columbia. Participants who started cART between 1996 and 2014 were followed until April 2016. Equality of proportions test was used to compare the percentage of participants with acquired drug resistance (ADR) or transmitted drug resistance (TDR) in 1996, to those in 2014. Kaplan-Meier was used to estimate time to ADR in four drug resistance categories. Multivariable regression odds ratios (OR) of ADR for select clinical variables were determined by 5-year eras of cART initiation. RESULTS: The proportion of individuals with ADR declined from 39% (51/132) to 3% (8/322) in 1996-2014 (p <0.0001), while the proportion with TDR increased from 12% (16/132) to 18% (59/322) (p 0.14). The estimated proportions of individuals with ADR rose to 29% (NNRTI), 28% (3TC/FTC), 14% (other nRTI), and 7% (PI) after >16 years of therapy. After 5 years on therapy, participants initiating cART in 1996-2000 had 5.5-times more 3TC/FTC ADR, 5.3-times more other nRTI ADR, 4.7-times more NNRTI ADR, and 24-times more PI ADR than those starting in 2011-2014. The individuals with highest odds of developing ADR in 1996-2010 were adherent to regimens at levels between 60% and 80%, which shifted to <40% adherent in 2011-2014. CONCLUSIONS: HIV drug resistance transitioned from being primarily selected de-novo to being driven by TDR. Among those who started treatment in the past 5 years, ADR is rare and observed mostly in the lowest adherence strata.
OBJECTIVES: We aim to identify long-term trends in HIV drug resistance before and after combined antiretroviral therapy (cART) initiation. METHODS: IAS-USA (2015) mutations were identified in 23 271 HIV protease-reverse transcriptase sequences from 6543 treatment naïve adults in British Columbia. Participants who started cART between 1996 and 2014 were followed until April 2016. Equality of proportions test was used to compare the percentage of participants with acquired drug resistance (ADR) or transmitted drug resistance (TDR) in 1996, to those in 2014. Kaplan-Meier was used to estimate time to ADR in four drug resistance categories. Multivariable regression odds ratios (OR) of ADR for select clinical variables were determined by 5-year eras of cART initiation. RESULTS: The proportion of individuals with ADR declined from 39% (51/132) to 3% (8/322) in 1996-2014 (p <0.0001), while the proportion with TDR increased from 12% (16/132) to 18% (59/322) (p 0.14). The estimated proportions of individuals with ADR rose to 29% (NNRTI), 28% (3TC/FTC), 14% (other nRTI), and 7% (PI) after >16 years of therapy. After 5 years on therapy, participants initiating cART in 1996-2000 had 5.5-times more 3TC/FTC ADR, 5.3-times more other nRTI ADR, 4.7-times more NNRTI ADR, and 24-times more PI ADR than those starting in 2011-2014. The individuals with highest odds of developing ADR in 1996-2010 were adherent to regimens at levels between 60% and 80%, which shifted to <40% adherent in 2011-2014. CONCLUSIONS: HIV drug resistance transitioned from being primarily selected de-novo to being driven by TDR. Among those who started treatment in the past 5 years, ADR is rare and observed mostly in the lowest adherence strata.
Keywords:
AIDS; Acquired drug resistance; Adherence; Antiretroviral drug resistance; BC Centre for Excellence in HIV/AIDS; Canada; HAART; HIV; Longitudinal; Transmitted drug resistance
Authors: Marta Pingarilho; Victor Pimentel; Mafalda N S Miranda; Ana Rita Silva; António Diniz; Bianca Branco Ascenção; Carmela Piñeiro; Carmo Koch; Catarina Rodrigues; Cátia Caldas; Célia Morais; Domitília Faria; Elisabete Gomes da Silva; Eugénio Teófilo; Fátima Monteiro; Fausto Roxo; Fernando Maltez; Fernando Rodrigues; Guilhermina Gaião; Helena Ramos; Inês Costa; Isabel Germano; Joana Simões; Joaquim Oliveira; José Ferreira; José Poças; José Saraiva da Cunha; Jorge Soares; Júlia Henriques; Kamal Mansinho; Liliana Pedro; Maria João Aleixo; Maria João Gonçalves; Maria José Manata; Margarida Mouro; Margarida Serrado; Micaela Caixeiro; Nuno Marques; Olga Costa; Patrícia Pacheco; Paula Proença; Paulo Rodrigues; Raquel Pinho; Raquel Tavares; Ricardo Correia de Abreu; Rita Côrte-Real; Rosário Serrão; Rui Sarmento E Castro; Sofia Nunes; Telo Faria; Teresa Baptista; Maria Rosário O Martins; Perpétua Gomes; Luís Mendão; Daniel Simões; Ana Abecasis Journal: Front Microbiol Date: 2022-04-25 Impact factor: 5.640
Authors: Oliver T Stirrup; David T Dunn; Anna Tostevin; Caroline A Sabin; Anton Pozniak; David Asboe; Alison Cox; Chloe Orkin; Fabiola Martin; Patricia Cane Journal: AIDS Res Ther Date: 2018-04-16 Impact factor: 2.250
Authors: Joel O Wertheim; Alexandra M Oster; Ben Murrell; Neeraja Saduvala; Walid Heneine; William M Switzer; Jeffrey A Johnson Journal: Virus Evol Date: 2018-12-04
Authors: Jielin Zhu; Ignacio Rozada; Jummy David; David M Moore; Silvia A Guillemi; Rolando Barrios; Julio S G Montaner; Viviane D Lima Journal: EClinicalMedicine Date: 2019-07-10
Authors: Soo-Yon Rhee; Dana Clutter; W Jeffrey Fessel; Daniel Klein; Sally Slome; Benjamin A Pinsky; Julia L Marcus; Leo Hurley; Michael J Silverberg; Sergei L Kosakovsky Pond; Robert W Shafer Journal: Clin Infect Dis Date: 2019-01-07 Impact factor: 9.079
Authors: Oliver T Stirrup; Caroline A Sabin; Andrew N Phillips; Ian Williams; Duncan Churchill; Anna Tostevin; Teresa Hill; David T Dunn Journal: J Virus Erad Date: 2019-11-04